Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prithviraj Bose

Showing results (81-90 of 224) with videos related to

Pageof 23
Sort By:
Anticancer Research|December 1, 2010
c-Kit expression and mutations in phyllodes tumors of the breastPrithviraj Bose, S Terence Dunn, Jian Yang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 19, 2025
Ruxolitinib Meets a Forgotten MaladyJennifer Makhoul, Chia-Yu Chiu, Cindy Berthelot, et al.
American Journal of Hematology|June 2, 2009
Successful treatment of cyclic thrombocytopenia with thrombopoietin-mimetic agents: a report of two patientsPrithviraj Bose, Khader K Hussein, Deirdra R Terrell, et al.
Blood|September 20, 2023
Moving toward disease modification in polycythemia veraJan Philipp Bewersdorf, Joan How, Lucia Masarova, et al.
Acta Haematologica|September 12, 2023
Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More YearsLucia Masarova, Prithviraj Bose, Naveen Pemmaraju, et al.
Current Hematologic Malignancy Reports|May 3, 2025
Emerging Therapeutic Approaches for Anemia in MyelofibrosisHelen T Chifotides, Andrea Duminuco, Elena Torre, et al.
Annals of Hematology|October 15, 2025
Results from a US modified Delphi consensus to define disease progression and disease modification in polycythemia VeraPrithviraj Bose, Emily Nagler, Muhammad Sarfraz Nawaz, et al.
European Journal of Haematology|December 12, 2017
Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosisLucia Masarova, Ahmad Alhuraiji, Prithviraj Bose, et al.
Current Hematologic Malignancy Reports|October 8, 2025
Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia VeraMinghui Duan, Prithviraj Bose, Anthony M Hunter, et al.
Leukemia & Lymphoma|August 6, 2016
Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical studyKiran Naqvi, Naval Daver, Naveen Pemmaraju, et al.
Pageof 23

Showing results (81-90 of 224) with videos related to

Sort By:
Pageof 23
Anticancer Research|December 1, 2010
c-Kit expression and mutations in phyllodes tumors of the breastPrithviraj Bose, S Terence Dunn, Jian Yang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 19, 2025
Ruxolitinib Meets a Forgotten MaladyJennifer Makhoul, Chia-Yu Chiu, Cindy Berthelot, et al.
American Journal of Hematology|June 2, 2009
Successful treatment of cyclic thrombocytopenia with thrombopoietin-mimetic agents: a report of two patientsPrithviraj Bose, Khader K Hussein, Deirdra R Terrell, et al.
Blood|September 20, 2023
Moving toward disease modification in polycythemia veraJan Philipp Bewersdorf, Joan How, Lucia Masarova, et al.
Acta Haematologica|September 12, 2023
Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More YearsLucia Masarova, Prithviraj Bose, Naveen Pemmaraju, et al.
Current Hematologic Malignancy Reports|May 3, 2025
Emerging Therapeutic Approaches for Anemia in MyelofibrosisHelen T Chifotides, Andrea Duminuco, Elena Torre, et al.
Annals of Hematology|October 15, 2025
Results from a US modified Delphi consensus to define disease progression and disease modification in polycythemia VeraPrithviraj Bose, Emily Nagler, Muhammad Sarfraz Nawaz, et al.
European Journal of Haematology|December 12, 2017
Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosisLucia Masarova, Ahmad Alhuraiji, Prithviraj Bose, et al.
Current Hematologic Malignancy Reports|October 8, 2025
Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia VeraMinghui Duan, Prithviraj Bose, Anthony M Hunter, et al.
Leukemia & Lymphoma|August 6, 2016
Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical studyKiran Naqvi, Naval Daver, Naveen Pemmaraju, et al.
Pageof 23